Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATXI Stock Price Chart Interactive Chart >
ATXI Price/Volume Stats
| Current price | $1.10 | 52-week high | $16.65 |
| Prev. close | $1.06 | 52-week low | $0.98 |
| Day low | $1.07 | Volume | 47,700 |
| Day high | $1.11 | Avg. volume | 1,025,145 |
| 50-day MA | $1.23 | Dividend yield | N/A |
| 200-day MA | $2.75 | Market Cap | 5.59M |
Avenue Therapeutics, Inc. (ATXI) Company Bio
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.
Latest ATXI News From Around the Web
Below are the latest news stories about AVENUE THERAPEUTICS INC that investors may wish to consider to help them evaluate ATXI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! |
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate UpdatesCompany to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it will participate in a Type C meeting with the FDA on March 9, 2023 to discuss a proposed study protocol to assess the risk of respirat |
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular AtrophyAJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapyMIAMI, March 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has entered into |
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)Aegis Capital Corp.acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). |
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private PlacementMIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional accredited investor. The Company issued 1,940,299 shares of common stock and pre-funded warran |
ATXI Price Returns
| 1-mo | -0.90% |
| 3-mo | -5.17% |
| 6-mo | -89.09% |
| 1-year | -85.73% |
| 3-year | -99.13% |
| 5-year | -98.37% |
| YTD | -5.17% |
| 2022 | -91.48% |
| 2021 | -84.74% |
| 2020 | -38.02% |
| 2019 | 77.78% |
| 2018 | 49.17% |
Loading social stream, please wait...